Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02431676 · ClinicalTrials.gov registry record · Phase 2
Survivorship Promotion In Reducing IGF-1 Trial
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT02431676 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 121 participants.
The verdict
NCT02431676, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a prospective, single-center randomized trial with three arms, and an allocation ratio of 1:1:1. The study design is an efficacy study to evaluate the effect of metformin and coach-directed behavioral weight loss versus self-directed weight loss on insulin-like growth factor (IGF)-1 and IGF-1 to THE IGFBP-III ratio blood levels after 6 and 12 months of intervention. The coach-directed Behavioral Weight Loss arm is a web-based remote delivery and communication system that promotes healthy behavioral changes. The Metformin arm is a pharmaceutical intervention of oral metformin. This is a secondary prevention study for men and women who have survived solid malignant tumors
Interventions
- DRUG Metformin
- BEHAVIORAL Coach Directed Behavioral Weight Loss
- BEHAVIORAL Self-control weight loss
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2015-05 |
| Est. Completion | 2018-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02431676
The ClinicalTrials.gov registry entry for NCT02431676 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT02431676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02431676 about?
NCT02431676 is a clinical study titled "Survivorship Promotion In Reducing IGF-1 Trial". This is a prospective, single-center randomized trial with three arms, and an allocation ratio of 1:1:1. The study design is an efficacy study to evaluate the effect of metformin and coach-directed behavioral weight loss versus self-directed weight loss on insulin-like growth factor (IGF)-1 and IGF-...
What is the current status of trial NCT02431676?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2015-05. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02431676?
The interventions under investigation include: Metformin (DRUG), Coach Directed Behavioral Weight Loss (BEHAVIORAL), Self-control weight loss (BEHAVIORAL).
Who is sponsoring clinical trial NCT02431676?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.